Research programme: AMPK activators - Betagenon/iNovacia

Drug Profile

Research programme: AMPK activators - Betagenon/iNovacia

Alternative Names: BG 8702; BG800 compounds; BG800 project

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Betagenon
  • Class Small molecules
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Type 2 diabetes mellitus

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Sweden (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in United Kingdom (PO)
  • 15 Sep 2008 Betagenon and iNovacia agree to collaborate in the discovery and optimisation of Betagenon's compounds in Sweden
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top